Physician profile
James Choe
NPI 1093075707
$9,749.56
in general payments reported to CMS, 2019-2025
41 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $694 · 2021: $1,575 · 2022: $1,817 · 2023: $1,265 · 2024: $1,556 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,717.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,104.36 | 2019-2023 | Farxiga, Lokelma |
| Novo Nordisk INC | $784.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $779.79 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $669.44 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $578.88 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $521.22 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $464.51 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $451.97 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $300.75 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.25 | 2020-2025 | Jardiance, Tradjenta |
| Corcept Therapeutics | $225.55 | 2022-2025 | Korlym |
| Mannkind Corporation | $185.98 | 2021-2025 | Afrezza |
| Sequel Med Tech, LLC | $175.44 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $148.31 | 2023-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $147.35 | 2022-2025 | Isturisa |
| Ultragenyx Pharmaceutical INC. | $143.12 | 2021-2022 | |
| Nevro Corp. | $130.56 | 2022-2024 | Senza |
| Abbvie INC. | $122.75 | 2021-2025 | Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $88.44 | 2023-2025 | |
| Cequr Corporation | $78.20 | 2024-2025 | Cequr Simplicity |
| Kyowa Kirin, INC. | $74.29 | 2023-2024 | Crysvita |
| Amgen INC. | $59.78 | 2024-2025 | Tepezza |
| Exact Sciences Corporation | $59.51 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $52.35 | 2022-2025 | Minimed 780g |
| Vistapharm, INC. | $46.42 | 2021 | |
| Glaxosmithkline, LLC. | $46.37 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Radius Health, INC. | $45.34 | 2025 | Tymlos |
| Halozyme INC | $37.36 | 2023 | |
| Antares Pharma, INC. | $33.80 | 2022-2023 | Tlando, Nocdurna, Xyosted |
| Zealand Pharma US, INC. | $27.69 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $27.39 | 2025 | Imcivree |
| Madrigal Pharmaceuticals | $24.61 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $22.08 | 2019 | |
| Horizon Therapeutics Plc | $21.06 | 2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $20.18 | 2025 | Unithroid |
| Eusa Pharma (US) LLC | $20.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.50 | 2025 | |
| Eisai INC. | $15.09 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.65 | 2025 | Nuzyra |
| Tosoh Bioscience, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.